Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON BACHARACH

Allopathic & Osteopathic Physicians Ophthalmology Glaucoma Specialist

NPI
1639160112
CMS profile
28253
Location
PETALUMA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$252,865.24

272 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $120,449.17 116
Thea Pharma Inc. $30,575.48 12
Alcon Vision LLC $19,730.31 37
Bausch & Lomb Americas Inc. $17,589.39 32
Glaukos Corporation $16,565.50 15
Sight Sciences, Inc. $15,271.70 16
Sun Pharmaceutical Industries Inc. $11,720.72 20
Alcon Research LLC $6,930.50 4
Carl Zeiss Meditec, Inc. $4,200.00 1
Oyster Point Pharma, Inc. $3,761.77 9
Horizon Therapeutics plc $3,087.77 4
Dompe US, Inc. $2,294.59 2
EyePoint Pharmaceuticals US, Inc. $525.00 1
Harrow Eye, LLC $124.72 1
Beaver-Visitec International, Inc. $25.37 1
NEW WORLD MEDICAL,INC. $13.25 1

Page 2 of 6; records 51–100 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON BACHARACH

NPI 1639160112 · CMS profile ID 28253

Allopathic & Osteopathic Physicians / Ophthalmology / Glaucoma Specialist

PETALUMA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639160112?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON BACHARACH, NPI 1639160112, CMS profile ID 28253. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639160112?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JASON BACHARACH, NPI 1639160112, CMS profile ID 28253. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639160112?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JASON BACHARACH, NPI 1639160112, CMS profile ID 28253, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639160112?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

272 matching records · $252,865.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 272 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 272.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bausch & Lomb Americas Inc. $2,900.0010/16/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037740985 CMS
Bausch & Lomb Americas Inc. $1,450.0010/16/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741081 CMS
AbbVie Inc. $4,550.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185747 CMS
AbbVie Inc. $4,550.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185749 CMS
AbbVie Inc. $3,250.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185751 CMS
AbbVie Inc. $3,250.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185753 CMS
AbbVie Inc. $1,950.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185755 CMS
Thea Pharma Inc. $8,108.2910/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005756563 CMS
Bausch & Lomb Americas Inc. $26.2010/09/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037740989 CMS
Bausch & Lomb Americas Inc. $50.7510/09/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037740993 CMS
Bausch & Lomb Americas Inc. $62.8810/09/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037741001 CMS
Bausch & Lomb Americas Inc. $7.0010/09/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037741005 CMS
Bausch & Lomb Americas Inc. $2,900.0010/09/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741009 CMS
Alcon Vision LLC $36.0010/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995620515 CMS
AbbVie Inc. $113.2810/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185745 CMS
AbbVie Inc. $1,950.0010/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185743 CMS
Bausch & Lomb Americas Inc. $124.9810/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741027 CMS
Bausch & Lomb Americas Inc. $20.4810/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741069 CMS
Bausch & Lomb Americas Inc. $150.0009/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037740983 CMS
Bausch & Lomb Americas Inc. $121.2109/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037740997 CMS
AbbVie Inc. $9.6709/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185741 CMS
Alcon Vision LLC $1,140.0009/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001556485 CMS
AbbVie Inc. $20.9309/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185725 CMS
AbbVie Inc. $19.5309/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185727 CMS
AbbVie Inc. $527.1109/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185729 CMS
AbbVie Inc. $522.5909/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185731 CMS
AbbVie Inc. $2,102.3709/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185733 CMS
AbbVie Inc. $41.9209/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185735 CMS
AbbVie Inc. $87.9309/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185737 CMS
AbbVie Inc. $114.3009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185739 CMS
AbbVie Inc. $38.9209/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185721 CMS
AbbVie Inc. $39.9609/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185723 CMS
Thea Pharma Inc. $184.3809/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005756555 CMS
AbbVie Inc. $18.3009/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185719 CMS
Alcon Vision LLC $7.0009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001556359 CMS
Alcon Vision LLC $53.7509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001556415 CMS
Alcon Vision LLC $3,135.0009/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001556525 CMS
AbbVie Inc. $1,950.0009/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185717 CMS
Bausch & Lomb Americas Inc. $24.9309/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741061 CMS
Glaukos Corporation $25.6808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059860859 CMS
Oyster Point Pharma, Inc. $20.0308/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052772133 CMS
Alcon Vision LLC $22.8608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995620495 CMS
Alcon Vision LLC $130.7908/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995620533 CMS
Bausch & Lomb Americas Inc. $382.0408/23/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037741019 CMS
Bausch & Lomb Americas Inc. $377.8108/23/2023 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1037741023 CMS
AbbVie Inc. $4,550.0008/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185715 CMS
AbbVie Inc. $17.9408/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996185713 CMS
Bausch & Lomb Americas Inc. $725.0008/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037741065 CMS
Thea Pharma Inc. $24.5608/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005756547 CMS
Sun Pharmaceutical Industries Inc. $56.9108/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053867251 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $216,257.12 366
PY2020 $217,996.08 232
PY2021 $217,356.59 270
PY2022 $239,632.47 312
PY2023 $252,865.24 272
PY2024 $241,718.15 307
PY2025 $269,623.54 302

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,500.00 2
PY2025 Principal investigator $62,044.50 14
PY2024 Principal investigator $58,939.80 10
PY2023 Recipient $2,800.00 1
PY2023 Principal investigator $59,994.97 30
PY2022 Principal investigator $126,546.68 50
PY2021 Principal investigator $137,407.14 40
PY2020 Principal investigator $185,667.62 81
PY2019 Recipient $12,876.70 3
PY2019 Principal investigator $156,653.10 85

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $10,093.00 11/05/2025 Non-covered Recipient Entity
NORTH BAY EYE ASSOCIATES INC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202521525
Principal investigator 1 Oyster Point Pharma, Inc. $3,267.00 10/15/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523082
Principal investigator 1 Oyster Point Pharma, Inc. $6,849.00 10/15/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523084
Principal investigator 1 ABBVIE INC. $221.60 10/09/2025 Non-covered Recipient Entity
NORTH BAY EYE ASSOCIATES INC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202514667
Principal investigator 1 Oyster Point Pharma, Inc. $3,072.60 08/14/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523078
Principal investigator 1 Oyster Point Pharma, Inc. $5,142.60 08/14/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523080
Recipient Sight Sciences, Inc. $1,500.00 07/03/2025 Covered Recipient Physician A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) No dispute reported 06/30/2026 1244586232
Recipient Ocular Therapeutix, Inc. $1,000.00 06/30/2025 Covered Recipient Physician A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) No dispute reported 06/30/2026 1250229287
Principal investigator 1 Oyster Point Pharma, Inc. $5,245.20 06/13/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523074
Principal investigator 1 Oyster Point Pharma, Inc. $4,609.80 04/28/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523072
Principal investigator 1 Oyster Point Pharma, Inc. $3,407.40 04/28/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523076
Principal investigator 1 Sight Sciences, Inc. $3,000.00 04/03/2025 Non-covered Recipient Entity
North Bay Eye Associates Inc.
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (EVOLVE) No dispute reported 06/30/2026 1244586150
Principal investigator 1 Oyster Point Pharma, Inc. $4,156.20 03/19/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523070
Principal investigator 1 Glaukos Corporation $513.30 02/12/2025 Non-covered Recipient Entity
North Bay Eye Associates
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% No dispute reported 06/30/2026 1250907530
Principal investigator 1 Oyster Point Pharma, Inc. $3,299.40 02/10/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523068
Principal investigator 1 Oyster Point Pharma, Inc. $9,167.40 01/17/2025 Non-covered Recipient Entity
North Bay Eye Associates
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis No dispute reported 06/30/2026 1238523066